Assignment no.1 On

CIPLA LTD CO.

Submitted by : Submitted to :Sarita kumari Mrs. Rajni Madam

Roll no. -50

DESH BHAGAT UNVERSITY OF MANGEMENT AND COMPUTER SCIENCE

WHO IS CIPLA &WHAT DO THEY DO

WHO1. The Chemical, Industrial & Pharmaceutical Laboratories;

2. Founded by Khwaja Abdul Hamid in the year 1935; and

3. On August 17,1935, Cipla was registered as a public limited company.

WHAT

1. Today Cipla is a leading player in anti-infective and anti- asthmatic formulation;

2. Specializes in the manufacturing of steroids and hormones ; and

3. Cipla has time and again earned the distinction of coming out with pioneering and life saving drugs.

Shareholders (as on 30-September-2013) Shareholding

Promoter Group 36.80%

Foreign Institutional Investors (FII) 23.78%

Individual shareholders 18.67%

Insurance companies 06.59%

Private Corporate Bodies 05.11%

Mutual Funds and UTI 04.11%

NRI/FCB/Others 03.90%

GDRs 01.04%

Total 100.0%

Listings and shareholding

Cipla Products Sales Value (in Cr)

• Tablets n Capsules 3981.31

• Bulk Drugs 897.8

• Aerosols 617.48

• Liquids 512.5

• Creams 134.04

• Others 86.78

• Export Incentives 80.95

• Other services 31.03

• Sale of services 27.01

• Scrap 25.54

STP – Cipla Ltd

Segment HIV/AIDS, cancer, arthritis, respiratory, cardiovascular disease

Target Group Flavors and fragrances, OTC, prescription products, pesticides, agrochemicals

Positioning Developing life saving drugs

SWOT Analysis – Cipla Ltd

Strength 1. Has developed good positive image by providing support to cancer patients by issuing drugs at low cost

2. Imminent commencement of the Fixed-Dose combination for treatment of uncomplicated malaria to tackle the 200+ million cases globally

3. Initiation of „No Touch Breast Scan‟ a step forward in the screening technology in India.

Weakness 1. Strong competition from international and domestic giants means limited market share 2. Had faced problems during negative campaign by AHF

Opportunity 1. Can venture into Alzheimer‟s disease medication

2. Increased investment in the budding markets, to push expansion in the global economy

Threats 1. Constant price rises in India 2. Depreciation of Indian Rupee as

compared to US Dollar -Fluctuations in currency exchange rates

GAP Analysis of Cipla

LOCATION: African market is the major market,followed by US. It has also discovered Europe as a high potential market.

PRODUCT: Growth in domestic formulation is 12% -farbelow the industry average

RESEARCH: It‟s APIs are still about to reap benefitsand are

expected to grow after a few years

Mission and Vision CIPLA Ltd

• Mission - “To provide excellent quality health care facilities at reasonable cost”

• Vision – To build a healthier and hence, better, world. Unichem Labs

• Mission - “To be a caring pharmaceutical company helping to enhance health through quality products”

• Vision - "To be a global pharmaceutical company with increasing focus on innovative research and developed markets."

• Raw materials – Backward Integration as well as horizontal Integration

• Low Debt/Equity Ratio of Unichem

• Strong Subsidiary in European Market – Niche Generics

• Rich US pipeline - Unichem Pharmaceuticals (USA) Inc. – several ANDA in pipeline

• Presence across diversified therapeutic classes

APPLICABILITY

• The Corporate Social Responsibility (CSR) Policy of Cipla Limited (“Company”) has been framed and made applicable in accordance with section 135 of the Act read with the Rules.

• The Policy shall apply to the CSR Committee and all CSR projects/programmes undertaken by the Company in accordance with Schedule VII of the Act.

Corporate Social Responsibility (CSR) CSR COMMITTEE • CSR Committee of the Board has been formed as required under the Act.

CSR EXPENDITURE • CSR expenditure shall include all expenditure including contribution

to corpus, for projects or programmes relating to CSR activities approved by the Board on the recommendation of the CSR Committee, but does not include any expenditure on an item not in conformity or not in line with activities which fall within the purview of the Schedule VII of the Act.

EXECUTION, MONITORING & REPORTING The CSR Committee shall: • Prepare and propose the CSR plan with the execution modalities and

implementation schedules to the Board. • Periodically appraise the Board on the status of the CSR plan. • Institute a transparent monitoring mechanism for implementation of the

CSR projects, programmes or activities undertaken by the Company.